Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
PTGX
PTGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PTGX News
Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
Mar 02 2026
Newsfilter
Protagonist Therapeutics Reports Q4 Earnings Miss
Feb 25 2026
seekingalpha
BVF Fully Exits Protagonist Therapeutics with $170.12 Million Sale
Feb 25 2026
Fool
Protagonist Therapeutics Executive Executes Large Stock Sale
Feb 16 2026
Fool
Protagonist Therapeutics CMO Sells Shares in Major Transaction
Feb 01 2026
Fool
Protagonist Therapeutics Executive Sells Shares
Feb 01 2026
NASDAQ.COM
Protagonist CMO Sells 9,514 Shares for $784K to Cover Taxes
Feb 01 2026
Yahoo Finance
Takeda Submits NDA for Rusfertide, Potential $400M Opt-Out Payment
Jan 05 2026
NASDAQ.COM
S&P 500 Futures Rise in Pre-Market Trading; Blue Hat Interactive and Sunoco Take the Lead
Jan 02 2026
Barron's
Protagonist and Takeda Present New 52-Week Results for PV Study at ASH
Dec 06 2025
Businesswire
Protagonist and Takeda Present 52-Week Results of Rusfertide Study
Dec 06 2025
Newsfilter
Protagonist and Takeda Present 52-Week Rusfertide Data for Polycythemia Vera
Dec 06 2025
NASDAQ.COM
Transcript of Protagonist (PTGX) Earnings Call
Nov 27 2025
NASDAQ.COM
Protagonist Therapeutics Achieves Analyst Price Target
Nov 26 2025
NASDAQ.COM
Citigroup Reaffirms Buy Rating on Protagonist Therapeutics and Increases Price Target to $98
Nov 10 2025
Benzinga
Barclays Keeps Overweight Rating on Protagonist Therapeutics and Increases Price Target to $88
Nov 07 2025
Benzinga
Show More News
